Digoxin, a cardiac glycoside, is mainly prescribed for patients with congestive heart failure. Cardiac arrhythmia sometimes occurs in patients who are taking digoxin, 1,2) and thus antiarrhythmic drugs were often co-administrated with digoxin. In fact, antiarrhythmic or antianginal drugs were also prescribed for 25% and 21% of patients taking digoxin, respectively, in our hospital.
PK 1 and LLC-GA5-COL150 Cell Monolayers
Transcellular transport of [ 3 H]digoxin across LLC-PK 1 and LLC-GA5-COL150 cell monolayers was examined as described previously. 3, 15, [17] [18] [19] Cells were seeded on Transwell TM (Cat. No. 3414, Costar, Cambridge, MA) at a density of 2.0ϫ10 6 and 2.4ϫ10 6 cells/well, respectively, and cultured under a humidified atmosphere of 5% CO 2 -95% air at 37°C for 3 d to form the monolayers. The MDR1 was highly expressed on the apical membrane in LLC-GA5-COL150 cell monolayers which accelerated the basal-to-apical transport (renal secretion) and inhibited the apical-to-basal transport (reabsorption). Basal-to-apical and apical-to-basal were examined independently. Three hours prior to the start of transport experiments, the culture medium was replaced with fresh culture medium. Colchicine was not included even for LLC-GA5-COL150 cells. The transport study was initiated by replacement of the culture medium on the donor side (basal or apical side) with 2 ml fresh culture medium containing [ 3 H]digoxin (100 nM, 18.5 kBq/ml) together with [methoxy-14 C]inulin (6.0 mM, 1.85 kBq/ml), used as a cell monolayer integrity marker, and that on the receiver side (apical or basal, respectively) with 2 ml fresh culture medium. The monolayers were incubated at 37°C, and 25 ml aliquots of the medium were sampled from the receiver side at three points (1, 2, 3 h). The data was accepted when the appearance of [methoxy- 14 C]inulin on the receiver side was less than 0.4% per h of the initial amount on the donor side.
The effects of antiarrhythmic and antianginal drugs on the transcellular transport of [ 3 H]digoxin were evaluated by their addition to both sides of the monolayers at 1 h before the start of the transport experiments, and at the start of the transport experiments. The cells were exposed to them for 4 h total. The concentration of antiarrhythmic and antianginal drugs was 50 mM, which was used in the previous reports. 3, [17] [18] [19] Although this is high, it is convenient to compare with the results on the previous reports. 3, [17] [18] [19] The radioactivity associated with the collected media was counted in 3 ml of ACS II (Amersham International) by liquid scintillation counting (LSC-5100, Aloka Co., Ltd., Tokyo). Data are presented as the percentage fraction of the initial amount of total radioactivity added to the donor side.
Data Analysis Statistical analysis of the data was performed by one-way analysis of variance followed by Scheffe's post-hoc test (two-tailed), with pϽ0.05 considered significant.
The IC 50 values for amiodarone, DEA, quinidine and dipyridamole on [ 3 H]digoxin transport were estimated as described previously. 20, 21) The net basal-to-apical transport of [ 3 H]digoxin at 3 h was calculated by subtracting the apicalto-basal transport from the basal-to-apical transport at 3 h. At several concentrations, amiodarone, DEA, quinidine and dipyridamole caused inhibition of net basal-to-apical transport at 3 h, shown as the percentage of reduction as compared with net basal-to-apical transport in the absence of drug. The percentage inhibition of net basal-to-apical transport at 3 h was plotted against the concentration of amiodarone, DEA, quinidine and dipyridamole, and fitted to the sigmoid E max model by nonlinear least-squares fitting method (Solver, Microsoft ® Excel 98).
Where E is the percentage inhibition (%) by amiodarone, DEA and dipyridamole on net basal-to-apical transport of [ 3 H]digoxin, E max is the maximum inhibition rate (that is, 100%), C is the concentration of amiodarone, DEA, quinidine and dipyridamole (mM) in the transport medium, IC 50 is the concentration (mM) producing 50% of E max , and g is the sigmoidicity factor. Table 2 ).
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Dipyridamole also significantly suppressed the basal-to-apical transport, and increased the apical-to-basal transport in LLC-GA5-COL150 cells, and its effect was concentration-dependent with an estimated IC 50 of 40.0 mM (Ta- independent experiments, except for basal-to-apical and apical-to-basal transport across LLC-PK 1 cell monolayers (nϭ9 and 8, respectively). Concentration of test drugs was 50 mM except for DEA at 10 mM. * pϽ0.05 significantly different from the respective groups of LLC-GA5-COL-150 cells. bles 1, 2, Fig. 3 ). In contrast, isosorbide showed only slight alteration of the transport (Table 1) .
DISCUSSION
In previous study using this experimental system, the estimated IC 50 values for nicardipine, verapamil, diltiazem and nifedipine on [ 3 H]digoxin transport were obtained to be 4.54 mM, 13.2 mM, 77.7 mM and 472 mM, respectively. 19) In clinical reports, nicardipine (60-90 mg/d) 13) and verapamil (240 mg/d) 11, 12) are known to increase digoxin serum concentrations in human, but diltiazem (90-180 mg/d) 22, 23) and nifedipine (55-60 mg/d) 24, 25) show no or only slight increase of serum concentrations. The total body clearance (l/h/kg) of these calcium antagonists are about 0.50, 0.80, 0.70 and 0.50, respectively, and the absolute bioavailability are about 40%, 20%, 40% and 60%, respectively, 26, 27) therefore the steady-state concentrations are calculated around 0.07-0.15 mM. The estimated IC 50 values are about 40-100 times these concentrations for nicardipine and verapamil, and more than 500-3000 times for diltiazem and nifedipine. Relatively higher concentration of [ 3 H]digoxin, 100 nM might be responsible for the discrepancies between the estimated IC 50 values and steady-state concentrations, and relatively higher expression of MDR1 compared with human renal epithelial cells presumably contribute. It is impossible to estimate the possibility of drug interaction with digoxin by direct comparison of the estimated IC 50 values and steady-state concentrations, however, the rank order of interaction might be estimated.
In this study, it has been indicated that amiodarone and DEA inhibited the transport of [ 3 H]digoxin transport with estimated IC 50 values of 5.48 and 1.27 mM, respectively (Table  2) . These are comparable to the steady-state plasma concentrations of 1.06 mg/ml (1.55 mM) and 1.04 mg/ml (1.59 mM) at a dose of 200 mg/d, respectively, 28) and MDR1 was suggested to be responsible for drug interaction with amiodarone, and that DEA contributed to the elevation of digoxin serum concentrations, although the comparison of concentrations of 29) These findings suggest that unexpected high serum concentrations of digoxin might occur several months following the discontinuation of amiodarone use. Quinidine also inhibited the transport of [ 3 H]digoxin transport with the estimated IC 50 value of 9.52 mM, being similar to the plasma concentration at a dose of 300 mg three times a day, 3.9-8.0 mM. 30) Thus, MDR1-based mechanism seems to be applied even for the interaction between digoxin and quinidine. Cibenzoline and lidocaine showed slight inhibition of the transport, and disopyramide and mexiletin had no such effects, suggesting their interaction with digoxin, if exists, is not due to MDR1.
Of the antianginal drugs, dipyridamole inhibited the transcellular transport of [ 3 H]digoxin in LLC-GA5-COL150 cells with the IC 50 of 40.0 mM ( Table 2 ). The maximum serum concentration of dipyridamole was around 2.0 mg/ml (4.0 mM) following a single oral administration of 100 mg, 31) and the initial whole blood concentration after intravenous administration of 20 mg was around 8.0 mg/ml (16.0 mM).
32)
The estimated IC 50 value is also only several times the achievable concentration in clinical use. Dipyridamole has been reported to increase the cytotoxicity of vinblastine and etoposide in drug-resistant tumor cells expressing MDR1. 33, 34) These findings indicate a risk of interactions. In conclusion, it has been demonstrated that MDR1 is responsible for the drug interaction between digoxin and amiodarone or quinidine reported in clinical use, and that active metabolite, DEA also contributes the elevation of digoxin serum concentrations in the case of amiodarone.
